Kate Sears

Hi I'm Kate, community lead for @OpenMedicineHQ. Open access and free for everyone.

[Kate Sears @OpenMedKate]

Link: https://t.co/GSARGJQgpi

[Kate Sears @OpenMedKate]

Finally had a chance to listen to @montypal and @ReginaBarCar on translating #ASCO26 research into practice in Latin America. Amazing podcast!

A few pearls 🧵

[Sumanta K. Pal, MD, FASCO @montypal]

You may have caught the great conversation with @batraatulonc that I had on the #ASCODailyNews Podcast, where we covered worldwide implications of plenary abstracts from #ASCO26. Now I had a chance to talk with @incanMX faculty member @ReginaBarCar on a similar topic, extending the discussion around regional impact from #Asia to #LATAM! Have a listen as we distill (in line with the vision of previous @ASCO President Eric Small) how data does (or does not!) percolate into different settings ...

[Kate Sears @OpenMedKate]

"The speed of implementation should always be matching the speed of scientific discovery." @ReginaBarCar

[Kate Sears @OpenMedKate]

@sanamloghavi @doctorpemm @mpdrc 🙏🙏🙏

[Kate Sears @OpenMedKate]

@FlavioRochaMD @OHSUKnight 🎉🎉🎉

[Oncology Brothers @OncBrothers]

ENDURANCE trial is the new SoC. But even around this data, practice differs. We were talking to @SagarLonialMD and their group is planning to extend treatment to perhaps 3yrs if MRD is positive at 2yr mark…

In my practice, I am following this trial. Thoughts @RahulBanerjeeMD @VincentRK @Myeloma_Doc @GKaurMD

[Kate Sears @OpenMedKate]

@Abdallah81MD @bmtdoc63 🎉🎉🎉

[Kate Sears @OpenMedKate]

@StephenVLiu @DrNeilLove @CashMuseum 🙂❤️

[Medical.watch @MedwatchHQ]

Amazing words from @marklewismd ♥️♥️♥️

[Kate Sears @OpenMedKate]

@nihardesai89 🙂❤️

[A.n.n. @fireflyann]

The algorithm is fascinating & extensive. Love the references for all the decision points.

Wish the graphic was a little less blurry as would love to share more widely.

Maybe a spot in graphic for 1st/2nd line trial consult? mountaineer 3, BbopCo all valid options

[Kate Sears @OpenMedKate]

@allisonoconn Gorgeous! 😍

[Kate Sears @OpenMedKate]

@jamecancerdoc @NCCN 🙂🙏

[Stephen V Liu, MD @StephenVLiu]

5y outcomes from phase III KEYNOTE-671: perioperative pembrolizumab vs neoadjuvant chemo for resectable NSCLC @Annals_Oncology.

5y EFS 49.9% vs 26.5% (HR 0.58) and 5y OS 64.6% vs 53.6% (HR 0.74) with no detriment to QoL with pembro vs placebo.

https://t.co/73LjhFfiqd

[Kate Sears @OpenMedKate]

@kidneycan @montypal @DrChoueiri Wow Toni! 👏👏👏

[Chinmay Jani @Jani_Chinmay]

Truly thankful to @EGFRResisters and @jillfeldman4 for the opportunity to be part of the EGFR Resisters Patient & Caregiver Summit in Chicago and for their continued leadership in patient advocacy and education. 💙

I shared our #ASCO26 work on AI in EGFR-mutant NSCLC, conducted in collaboration with @Larvol 🤖, along with practical ways patients can use AI to better understand medical information, explore clinical trials, compare treatment options, translate information, and prepare questions for clinic visits.

We also discussed the limitations of AI- and why it should support, not replace, conversations with the oncology team.
#EGFR #PatientAdvocacy #AI #NSCLC
@SylvesterCancer @GlopesMd @Latinamd @lcrf_org @LUNGevity @HemOncMiami @Cornerstone_CME @cancerGRACE

[Kate Sears @OpenMedKate]

@jillfeldman4 @Jani_Chinmay @EGFRResisters Chinmay 🙂❤️